⌕
Celldex Therapeutics · CLDX · Nasdaq
Tenet 44 · Weak
Compare
$28.04−1.92%At closeTenet 44 · Weak
$28.04−0.55 (−1.92%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Celldex Therapeutics (CLDX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

16 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 78% below its peak, net margin −16748.0%. Worth your attention in FY25: Share count (+54.9%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼78.0%
1.5
FY21→FY25CAGR −24.1%/yr
Net income ($M)▼63.9%
−258.8
FY21→FY25CAGR —
Free cash flow ($M)▼33.8%
−213.7
FY21→FY25CAGR —
Diluted EPS▼59.2%
−3.90
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+54.9%

42.9mn → 66.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$2.7M

+41.4% YoY in FY25 · 175.7% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1.5Revenue0.0COGS−245.1R&D−43.8SG&A−287.4Op income28.6Tax & other−258.8Net income

-16748¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

Net margin -16748.0% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
157.01,545.07,020.06,883.02,357.04,651.0▼78.0%−24.1%
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—A—A—A—A—A4,651.0——
Research & development
283,283.0245,074.0163,550.0118,011.082,258.053,311.0▲49.8%+46.4%
Selling, general & admin
51,337.043,838.038,548.030,914.027,195.020,488.0▲13.7%+20.9%
Total operating expenses
334,620.0288,912.0202,098.0161,425.0117,591.075,894.0▲43.0%+39.7%
Operating incomefeeds ROC rank
−334,463.0−287,367.0−195,078.0−154,542.0−115,234.0−71,243.0▼47.3%—
Other income, net
25,401.028,610.037,215.013,113.02,909.0505.0——
Pretax income
−309,062.0−258,757.0−157,863.0−141,429.0−112,325.0−70,738.0▼63.9%—
Income tax
—————−227.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−309,062.0−258,757.0−157,863.0−141,429.0−112,325.0−70,511.0▼63.9%—
Per share
Diluted EPSbuyback-sensitive
−4.31−3.90−2.45−2.92−2.40−1.64▼59.2%—
Diluted shares (mn)
78.5366.4264.3948.4546.8942.87▲3.1%+11.6%
Margins
Gross margin
—A—A—A—A—A100.0%——
Operating margin
−213033.8%−18599.8%−2778.9%−2245.3%−4889.0%−1531.8%▼15820.9pp−17068.0pp
Net margin
−196854.8%−16748.0%−2248.8%−2054.8%−4765.6%−1516.0%▼14499.3pp−15232.0pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Celldex Therapeutics' revenue last fiscal year?

Celldex Therapeutics reported revenue of $1.5M in fiscal 2025, down 78.0% from fiscal 2024.

What was Celldex Therapeutics' net income?

Celldex Therapeutics reported net income of −$258.8M in fiscal 2025, a net margin of −16748.0%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.